FDA Adverse Event Injury Summary report: N

UNKNOWN PARIETEX PRODUCT

MDR report key: 11891751 · Received May 27, 2021

Report

Report Number
9615742-2021-01392
Event Type
Injury
Date Received
May 27, 2021
Date of Event
July 14, 2020
Report Date
May 26, 2021
Manufacturer
SOFRADIM PRODUCTION SAS
Product Code
FTL
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

TITLE: TOTAL ENDOSCOPIC-ASSISTED LINEA ALBA RECONSTRUCTION (TESLAR) FOR TREATMENT OF UMBILICAL/PARAUMBILICAL HERNIA AND RECTUS ABDOMINUS DIASTASIS IS ASSOCIATED WITH UNACCEPTABLE PERSISTENT SEROMA FORMATION: A SINGLE CENTRE EXPERIENCE SOURCE: HERNIA (2020) 24:1379¿1385 HTTPS://DOI.ORG/10.1007/S10029-020-02266-8 RECEIVED: 20 MAY 2020 / ACCEPTED: 14 JULY 2020 / PUBLISHED ONLINE: 20 JULY 2020 © SPRINGER-VERLAG FRANCE SAS, PART OF SPRINGER NATURE 2020. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

ACCORDING TO LITERATURE SOURCE OF STUDY PERFORMED BETWEEN MARCH 2018 AND MAY 2019, TOTAL ENDOSCOPIC-ASSISTED LINEA ALBA RECONSTRUCTION WAS PERFORMED TO 21 PATIENTS AND PARIETEX WAS USED TO 3 PATIENTS. THE AIM OF THE STUDY WAS TO ESTABLISH THE RISKS AND BENEFITS OF SAFELY PERFORMING TOTAL ENDOSCOPIC-ASSISTED LINEA ALBA RECONSTRUCTION. ONE PATIENT SUFFERED FROM SEVERE POSTOPERATIVE INFECTED COLLECTION FOLLOWING THE PROCEDURE WHICH REQUIRED FORMAL WASHOUT AND REMOVAL OF THE MESH. OTHER POSTOPERATIVE COMPLICATIONS INCLUDE: SEROMA, CHRONIC PAIN, AND RECURRENCE. PATIENTS WITH SEROMAS UNDERWENT ASPIRATIONS AND REOPERATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
791837 UNKNOWN PARIETEX PRODUCT FTL SOFRADIM PRODUCTION SAS UNKNOWN PARIETEX PRODUCT

Patients

Seq Age Sex Outcome Treatment
1 Hospitalization| R